Compare Stocks: AXSM, JAZZ, ONC, and RPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$206.68 -0.8%	$223.81	$112.90 ▼ $260.19	$10.83B	0.71	669,213 shs	438,239 shs
JAZZ Jazz Pharmaceuticals	$246.81 -0.3%	$249.14	$123.88 ▼ $266.38	$16.02B	0.36	1.07 million shs	321,867 shs
ONC BeOne Medicines	$358.26 -1.2%	$333.94	$253.95 ▼ $385.22	$39.33B	0.51	386,971 shs	201,834 shs
RPRX Royalty Pharma	$63.96 +0.1%	$58.97	$34.08 ▼ $64.38	$36.78B	0.44	2.69 million shs	3.40 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.80%	+3.85%	-2.90%	-11.04%	+69.41%
JAZZ Jazz Pharmaceuticals	-0.31%	+0.93%	-5.64%	+3.45%	+87.37%
ONC BeOne Medicines	-1.22%	-2.31%	+9.38%	+32.64%	+6.54%
RPRX Royalty Pharma	+0.13%	+5.11%	+10.75%	+14.48%	+74.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$206.68 -0.8%	$223.81	$112.90 ▼ $260.19	$10.83B	0.71	669,213 shs	438,239 shs
JAZZ Jazz Pharmaceuticals	$246.81 -0.3%	$249.14	$123.88 ▼ $266.38	$16.02B	0.36	1.07 million shs	321,867 shs
ONC BeOne Medicines	$358.26 -1.2%	$333.94	$253.95 ▼ $385.22	$39.33B	0.51	386,971 shs	201,834 shs
RPRX Royalty Pharma	$63.96 +0.1%	$58.97	$34.08 ▼ $64.38	$36.78B	0.44	2.69 million shs	3.40 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.80%	+3.85%	-2.90%	-11.04%	+69.41%
JAZZ Jazz Pharmaceuticals	-0.31%	+0.93%	-5.64%	+3.45%	+87.37%
ONC BeOne Medicines	-1.22%	-2.31%	+9.38%	+32.64%	+6.54%
RPRX Royalty Pharma	+0.13%	+5.11%	+10.75%	+14.48%	+74.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.91	Moderate Buy	$267.60	29.48% Upside
JAZZ Jazz Pharmaceuticals	3.00	Buy	$285.44	15.65% Upside
ONC BeOne Medicines	3.00	Buy	$402.14	12.25% Upside
RPRX Royalty Pharma	3.00	Buy	$60.86	-4.85% Downside

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, ONC, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
8/28/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$299.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$277.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$283.00 ➝ $322.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$300.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$287.00 ➝ $300.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$264.00 ➝ $281.00
8/26/2026	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$292.00 ➝ $310.00
8/24/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$776.57M	13.94	N/A	N/A	$1.59 per share	129.99
JAZZ Jazz Pharmaceuticals	$4.27B	3.75	$16.22 per share	15.22	$73.97 per share	3.34
ONC BeOne Medicines	$6.13B	6.42	$3.86 per share	92.79	$47.13 per share	7.60
RPRX Royalty Pharma	$2.54B	14.50	$4.78 per share	13.37	$17.02 per share	3.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	50.91	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	17.02	11.13	0.22	20.45%	33.97%	13.02%	11/4/2026 (Estimated)
ONC BeOne Medicines	$286.93M	$5.68	63.07	26.28	N/A	10.70%	14.23%	7.82%	N/A
RPRX Royalty Pharma	$770.95M	$1.45	44.11	11.57	1.49	32.14%	30.01%	14.91%	11/4/2026 (Estimated)

Latest AXSM, JAZZ, ONC, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/5/2026	Q2 2026	ONC BeOne Medicines	$1.40	$2.05	+$0.65	$2.05	$1.66 billion	$1.71 billion
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	$1.32	+$0.05	$0.04	$758.93 million	$674.14 million
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.47%	+24.01%	64.83%	5 Years

Latest AXSM, JAZZ, ONC, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.6%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.52	1.43	1.34
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
ONC BeOne Medicines	0.17	3.40	3.06
RPRX Royalty Pharma	0.88	2.80	2.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
JAZZ Jazz Pharmaceuticals	89.14%
ONC BeOne Medicines	48.55%
RPRX Royalty Pharma	54.35%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
JAZZ Jazz Pharmaceuticals	4.10%
ONC BeOne Medicines	6.19%
RPRX Royalty Pharma	18.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	52.38 million	41.59 million	Optionable
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
ONC BeOne Medicines	12,000	109.79 million	102.99 million	N/A
RPRX Royalty Pharma	80	575.00 million	466.67 million	Optionable

AXSM, JAZZ, ONC, and RPRX Headlines

Recent News About These Companies

梯瓦制药（TEVA）与Royalty Pharma（RPRX）合作抗体药物TEV'408迎重大临床突破

September 4 at 7:52 PM | i.ifeng.comI

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

September 4 at 7:52 PM | finance.yahoo.com

Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen

September 4 at 7:05 PM | globenewswire.com

Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma

September 2 at 8:05 AM | msn.com

Public Employees Retirement System of Ohio Makes New $7.84 Million Investment in Royalty Pharma PLC $RPRX

September 2 at 4:48 AM | marketbeat.com

Royalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough

September 1, 2026 | insidermonkey.com

Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week High - What's Next?

September 1, 2026 | marketbeat.com

Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX

August 31, 2026 | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Downgraded to Buy Rating by Wall Street Zen

August 30, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy

August 30, 2026 | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Recommendation of "Buy" by Brokerages

August 29, 2026 | americanbankingnews.com

Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating

August 26, 2026 | seekingalpha.com

Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing

August 26, 2026 | seekingalpha.com

Odyssean LLC Acquires 21,401 Shares of Royalty Pharma PLC $RPRX

August 26, 2026 | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year High - Here's What Happened

August 25, 2026 | marketbeat.com

Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Brokerages

August 24, 2026 | marketbeat.com

Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to "Strong-Buy"

August 22, 2026 | marketbeat.com

Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,997,000.00 in Stock

August 20, 2026 | insidertrades.com

30,000 Shares in Royalty Pharma PLC $RPRX Purchased by Monetta Financial Services Inc.

August 20, 2026 | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) EVP Christopher Hite Sells 100,000 Shares of Stock

August 19, 2026 | marketbeat.com

Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - Here's What Happened

August 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AXSM, JAZZ, ONC, and RPRX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$206.68 -1.67 (-0.80%)

As of 09/4/2026 04:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Jazz Pharmaceuticals NASDAQ:JAZZ

$246.81 -0.76 (-0.31%)

As of 09/4/2026 04:00 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

BeOne Medicines NASDAQ:ONC

$358.26 -4.42 (-1.22%)

As of 09/4/2026 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Royalty Pharma NASDAQ:RPRX

$63.96 +0.08 (+0.13%)

As of 09/4/2026 04:00 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, ONC, and RPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AXSM, JAZZ, ONC, and RPRX Earnings

Compare Dividends

Latest AXSM, JAZZ, ONC, and RPRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AXSM, JAZZ, ONC, and RPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AXSM, JAZZ, ONC, and RPRX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Jazz Pharmaceuticals NASDAQ:JAZZ

BeOne Medicines NASDAQ:ONC

Royalty Pharma NASDAQ:RPRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools